IBRUTINIB + VENETOCLAX IN RELAPSED/REFRACTORY CLL.
The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Both significantly improve survival in CLL and replace chemoimmunotherapy for many patients. However, individually, they rarely lead to eradication of measurable residual disease (MRD) and usually are taken indefinitely or until progression. We […]
IBRUTINIB + VENETOCLAX IN RELAPSED/REFRACTORY CLL. Read More »
